Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC

Inclusion Criteria: * individuals aged 6-12 years (confirmed by birth certificate or similar document) * having given written informed consent signed by parents/caregivers * being able and willing to provide two stool samples at baseline and at follow-up assessment (14-21 days) * having at least two out of four Kato-Katz slides positive for T. trichiura at baseline * being able and willing to be examined by a study physician before and after treatment Exclusion Criteria: * presence or signs of major systemic illness, e.g. fever (temporal body temperature of \>38.0°C), severe anaemia (haemoglobin level of \<80 g/l) * history of severe acute disease or unmanaged, severe chronic disease (i.e., condition is not as therapeutically controlled as necessary) * use of anthelminthic drugs during study period * known allergy to study medication (i.e., moxidectin or albendazole) * being prescribed or taking concomitantly medication with known contraindications or drug interactions with the study medication * pregnancy (female participants aged 10-12 years) * concurrent participation in other clinical trials